2017 Korean Association for the Study of the Liver (KASL) Clinical Practice Guidelines of Chronic Hepatitis C: WhatGraves’s New?

Abstract

With the advent of highly effective direct-acting antiviral agents (DAA), the treatment of hepatitis C virus infections continues to change. The Korean Association for the Study of the Liver updated guidelines for the management of hepatitis C were revised in 2015 in accordance with the introduction of new DAA into practice and a results of domestic and overseas research in late 2017. More effective and convenient DAAs are also recommended for each genotype depending on the presence of cirrhosis and treatment experience. DAA treatment in patients with chronic kidney disease is feasible. The treatment guidelines for DAA failure are also presented. The guidelines need to be revised constantly as new drugs are developed and the results of clinical research and experience accumulate.

Keywords

• Hepatitis C
• Therapeutics
• Direct-acting antiviral agents
• Guideline